ProMIS Neurosciences Inc. (PMN)
ProMIS Neurosciences develops antibody therapies that target harmful misfolded proteins in neurodegenerative diseases such as Alzheimer's. It last closed at $3.21 on Nov 17, down 3.02% on the day.
Key Stats
Last 12 monthsNot reported for this period.
From PMN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 1 analyst who set a price target on PMN in the past 90 days. The average target is $15.00, with a high of $15.00 and a low of $15.00, compared with the last close of $3.21.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 2 | Roth Capital | Target lowered | Buy | $19 → $15 |
| Aug 14 | Guggenheim | Maintained | Buy | $100 |
| Jul 29 | Guggenheim | Maintained | Buy | $69 |
| Jul 28 | Chardan Capital | Target raised | Buy | $20 → $33 |
| Jul 27 | Chardan Capital | Initiated | Buy | $20 |
Technical Analysis
The stock is 75% below its 20 day and 174% below its 50 day average. It is 289% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 30), near oversold. The nearest support is the Pivot S1 at $3.08, and the nearest resistance the Pivot at $3.23.
| RSI (14) | 30.05 | Weak, oversold below 30 | Neutral |
| MACD | -1.69 | Below its signal line | Bearish |
| Stochastic | 5.5 | Near the bottom of its range | Oversold |
| ADX (14) | 32.5 | Trending down | |
| Williams %R | -95.0 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -63.4 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −4.6% | Change over 10 sessions | Bearish |
| ATR (14) | $0.93 | Typical daily range, 29.1% of price |
| RSI (14) | 29.79 | Oversold below 30 | Oversold |
| MACD | -2.31 | Below its signal line | Bearish |
| Stochastic | 5.7 | Near the bottom of its range | Oversold |
| ADX (14) | 24.3 | Weak trend | |
| Williams %R | -96.6 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -148.8 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −76.3% | Change over 10 sessions | Bearish |
| ATR (14) | $2.47 | Typical daily range, 76.9% of price |
What happened before
See how PMN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How PMN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2007.
Whale Options Flow
90DNo whale options trades in PMN in the last 90 days.
PMN Institutional Ownership
Full report →- ▲11 buying vs 8 selling
- ●Held by funds -0.4 pts
- ▲Funds holding +4
- ▲Superinvestors: 2 added, 0 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 31 | 27 | +14.8% |
| In funds' top 10 | 2 | 2 | 0.0% |
| Held by funds | 70.8% | 71.2% | −0.4 pts |
| New / increased | 7 / 4 | 4 / 7 | 0.0% |
| Reduced / sold out | 5 / 3 | 5 / 2 | +14.3% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PMN is in one of them and how their past PMN trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered PMN in an article yet. Here's the latest on the wider market.
About ProMIS Neurosciences
ProMIS Neurosciences is a biotechnology company based in Toronto, Canada, that is developing antibody therapies for neurodegenerative diseases. Its main program targets Alzheimer's disease, and its other candidates address conditions such as ALS and Parkinson's disease. The company uses a computational platform to find targets that appear only on the harmful, misfolded form of a protein, so its antibodies aim to leave the healthy form alone. The therapies are intended for patients with these conditions, and the company is still in clinical development.
- Headquarters
- Toronto, Ontario, Canada

